knowledge -WSS

knowledge

author：hotspot 2025-08-11 07:58:37 - browse：32283

Adobe

The Food and Drug Administration is expected to approve Merck’s drug to treat a rare lung disorder called pulmonary arterial hypertension on Tuesday, making available a novel treatment for a deadly condition that’s long been challenging to treat.

In a large trial published last year, the drug, called sotatercept, exceeded expectations in significantly increasing the distance that patients could walk and cutting the risk that their condition would worsen, that they would die, and that they would need new treatments.

Pulmonary arterial hypertension, or PAH, is estimated to occur in 15 to 50 per million people, mostly in women. It’s characterized by a proliferation of cells in the blood vessels that connect the right side of heart to the lungs, making it harder for blood to pass through and leading the heart to have to work harder to pump blood into the lungs. The disease, which causes difficulty breathing, fatigue and dizziness, has a high mortality rate, with one study finding that one-fifth of patients died at around three years after diagnosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Lab trade group sues FDA to halt regulation of lab

knowledge

WSS

Report: NIH

FDA clears AI tool for detecting skin cancer

Prosthetic arm enables patients to feel the objects they grip

Adam's Biotech Scorecard: Do Sarepta's exon

Insmed lung disease drug hits target in key Phase 3 trial

AI generated plenty of interest at JPM but not a lot of trust

leisure time

knowledge

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

Scientists successfully use ultrasound imaging to map brain activity

How one medical school became remarkably diverse

EU regulator recommends expanding Mounjaro approval to obesity

Hepatitis C has a cure — but many Americans still lack access to it

EU regulator recommends expanding Mounjaro approval to obesity

New air purifier tech could be key to improving indoor air quality

Copay coupons to count toward deductibles, after Biden court move

Affirmative action in medical school literally saved lives

How digital therapeutics firms are pivoting after Pear's bankruptcy

explore

The surgeon had a dilemma only a Nazi medical text could resolve

Readout Newsletter: Merck, J&J, and long Covid

Childbirth

Research misconduct: Proposed new rules face resistance

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Prosthetic arm enables patients to feel the objects they grip

hotspot

knowledge

explore

hotspot